KRAS and non-small cell lung carcinoma: A phase I trial demonstrated that sotorasib provided clinical benefit for KRAS G12C-mutated non-small cell lung cancers with an objective response rate of 32.2%, compared to only 7.1% for CRC, in patients with advanced solid tumors [57].